EUVIMEDEUVIMED entdecken
Crossref

Oral Decitabine/Cedazuridine Is an Effective Ambulatory Therapy for Patients With Myelofibrosis Refractory to JAK2 Inhibitor Therapy

Shivani Handa, Ganesh Sivakumar, Andrew Srisuwananukorn, Amylou Dueck, Douglas Tremblay, John O Mascarenhas, Yelena Ginzburg, Marina Kremyanskaya, Ronald Hoffman

Clinical Lymphoma Myeloma and Leukemia · 2024

DOI: 10.1016/j.clml.2024.05.012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2024. Verfasst von Shivani Handa und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology & Oncology, Department of Internal Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY. Hauptthemen laut MEDLINE: Primary Myelofibrosis, Decitabine, Janus Kinase 2. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Outcomes are dismal for patients with myelofibrosis (MF) who are no longer responsive to JAK2 inhibitors (JAKi) and/or have increasing blast cell numbers. Although prior reports have suggested the benefits of intravenous decitabine (DAC) combined with ruxolitinib for patients with Myeloproliferative Neoplasm (MPN) accelerated/blast phase (AP/BP), decitabine-cedazuridine (DEC-C), an oral fixed-dose combination providing equivalent pharmacokinetic exposure, has not been evaluated in MF. METHODS: We conducted a retrospective analysis of 14 patients with high-risk MF refractory to ruxolitinib or MPN-AP (10-19% blasts) treated with DEC-C +/- JAKi at Mount Sinai Hospital from 2021 to 2024. RESULTS: The cohort was elderly (median age,76 years) and almost uniformly possessed high risk mutations with 13 of the 14 patients progressing on JAKi therapy. With a median follow-up of 9.4 months, the median overall survival (OS) was 29 months for the entire cohort. Median OS was 10.8 months for MPN-AP and was not reached for ruxolitinib refractory MF patients. All patients (n = 9) receiving > 4 cycles of DEC-C had clinical benefit exemplified by a reduction in blast cell numbers, spleen size, and lack of progression to MPN-BP (78%). Furthermore, 3/14 patients proceeded to allogeneic stem cell transplant. Myelosuppression was a common adverse event which was managed by reducing the number of days of administration of DEC-C from 5 to 3 per cycle. CONCLUSIONS: This report demonstrates the feasibility, tolerability, and clinical benefit of an exclusively ambulatory regimen for high-risk, elderly patients with advanced MF which warrants further evaluation in a prospective clinical trial.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Primary MyelofibrosisDecitabineJanus Kinase 2HumansAgedMaleFemaleAged, 80 and overMiddle AgedRetrospective StudiesUridineAdministration, OralTreatment OutcomeAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

Chromatin-modifying agentHypomethylating agentMPN-accelerated phaseRuxolitinib-refractorymyeloproliferative neoplasms

Substanzen

DecitabineJanus Kinase 2cedazuridineJAK2 protein, humanUridine

Autor:innen und Institutionen

  • Division of Hematology & Oncology, Department of Internal Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
  • Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH.
  • Division of Hematology & Oncology, Department of Internal Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY; Division of Hematology, Department of Internal Medicine, The Ohio State…
  • Department of Quantitative Health Sciences, Mayo Clinic, Scottsdale, AZ.
  • Division of Hematology & Oncology, Department of Internal Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address: ronald.hoffman@mssm.edu.

Zitieren

APA

Handa, S., Sivakumar, G., Srisuwananukorn, A., Dueck, A., Tremblay, D., Mascarenhas, J. O., Ginzburg, Y., Kremyanskaya, M., & Hoffman, R. (2024). Oral Decitabine/Cedazuridine Is an Effective Ambulatory Therapy for Patients With Myelofibrosis Refractory to JAK2 Inhibitor Therapy. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2024.05.012

Vancouver

Handa S, Sivakumar G, Srisuwananukorn A, Dueck A, Tremblay D, Mascarenhas JO, et al. Oral Decitabine/Cedazuridine Is an Effective Ambulatory Therapy for Patients With Myelofibrosis Refractory to JAK2 Inhibitor Therapy. Clinical Lymphoma Myeloma and Leukemia. 2024. doi:10.1016/j.clml.2024.05.012

BibTeX
@article{Handa2024,
  author = {Handa, Shivani and Sivakumar, Ganesh and Srisuwananukorn, Andrew and Dueck, Amylou and Tremblay, Douglas and Mascarenhas, John O and Ginzburg, Yelena and Kremyanskaya, Marina and Hoffman, Ronald},
  title = {Oral Decitabine/Cedazuridine Is an Effective Ambulatory Therapy for Patients With Myelofibrosis Refractory to JAK2 Inhibitor Therapy},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2024},
  doi = {10.1016/j.clml.2024.05.012}
}
Kostenlos starten →